Edition:
United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

57.73USD
21 Jul 2017
Change (% chg)

$0.20 (+0.35%)
Prev Close
$57.53
Open
$57.50
Day's High
$58.05
Day's Low
$57.16
Volume
706,667
Avg. Vol
823,410
52-wk High
$63.40
52-wk Low
$41.93

Stejbach, Mark 

Mr. Mark P. Stejbach is Senior Vice President, Chief Commercial Officer of Alkermes PLC. Prior to assuming his current position, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, most recently as its Chief Commercial Officer. He previously held senior positions at Merck and Biogen Idec Inc. and has over 25 years of experience in biotech and pharmaceutical marketing, sales, managed care and finance. Mr. Stejbach currently serves on the board of directors for Flexion Therapeutics, a publicly traded pharmaceutical company. He previously served on the charitable board of the Commonwealth National Fund from 2003 through 2011 and has served on the Advisory Board of the Center for Value-Based Insurance Design since 2009.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

9,647,420

Shane Cooke

4,144,870

James Frates

2,678,060

Kathryn Biberstein

3,430,420

Elliot Ehrich

3,452,210

Iain Brown

--
As Of  30 Dec 2016